← Leaderboards
Benjamin G Bitler
Wistar Institute
$3,877,538
Attributed
$4,781,133
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,781,133 · 4
By mechanism
R37$1,998,601 · 1
R01$1,807,191 · 1
R00$745,313 · 1
K99$230,028 · 1
Top collaborators
- Matthew J Sikora3 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant Neoplasm Of OvaryCell LineSignal TransductionResistanceCancer CellNovel TherapeuticsCancer ModelBeta CateninInvestigationPathway InteractionsResponseGenesCellsAttenuatedEpithelial Ovarian CancerCancer Cell LineFutureMutateColoradoMediatingDisease ResistanceIn VitroClinical Management
Grant awards (16)
Elucidating a novel WNT4 regulatory axis as a driver of gynecologic cancer health disparities$595,487
R01 · FY2025 · CA
Targeting Wnt signaling in therapy-resistant ovarian cancer$358,851
R37 · FY2025 · CA · contact PI
Targeting Wnt signaling in therapy-resistant ovarian cancer$83,270
R37 · FY2025 · CA · contact PI
Elucidating a novel WNT4 regulatory axis as a driver of gynecologic cancer health disparities$566,139
R01 · FY2024 · CA
Targeting Wnt signaling in therapy-resistant ovarian cancer$333,493
R37 · FY2024 · CA · contact PI
Targeting Wnt signaling in therapy-resistant ovarian cancer$79,331
R37 · FY2024 · CA · contact PI
Elucidating a novel WNT4 regulatory axis as a driver of gynecologic cancer health disparities$645,565
R01 · FY2023 · CA
Targeting Wnt signaling in therapy-resistant ovarian cancer$344,577
R37 · FY2023 · CA · contact PI
Diversity Supplement - Targeting Wnt signaling in therapy-resistant ovarian cancer$81,678
R37 · FY2023 · CA · contact PI
Targeting Wnt signaling in therapy-resistant ovarian cancer$352,120
R37 · FY2022 · CA · contact PI
Targeting Wnt signaling in therapy-resistant ovarian cancer$365,281
R37 · FY2021 · CA · contact PI
Targeting Wnt signaling to overcome PARP inhibitor resistance in ovarian cancer$247,313
R00 · FY2019 · CA · contact PI
Targeting Wnt signaling to overcome PARP inhibitor resistance in ovarian cancer$249,001
R00 · FY2018 · CA · contact PI
Targeting Wnt signaling to overcome PARP inhibitor resistance in ovarian cancer$248,999
R00 · FY2017 · CA · contact PI
Targeting Wnt signaling to overcome PARP inhibitor resistance in ovarian cancer$115,014
K99 · FY2016 · CA · contact PI
Targeting Wnt signaling to overcome PARP inhibitor resistance in ovarian cancer$115,014
K99 · FY2015 · CA · contact PI